Matches in SemOpenAlex for { <https://semopenalex.org/work/W3048309245> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W3048309245 abstract "Background/Objective: With the increasing interest in natural products, a phase I openlabel study of OMN54 (Aneustat™) in patients with advanced malignancies was initiated to determine toxicity, maximum tolerated dose (MTD), dose limiting toxicities (DLT), and pharmacokinetics (PK). OMN54 is a multitargeted agent, combining three Chinese botanicals; Ganoderma lucidium, Salvia miltiorrhiza and Scutellaria barbata. Methods: Eligible patients (pts) were >18 years of age with advanced solid tumors, able to swallow oral capsules, ECOG performance status < 2, measurable disease as defined by RECIST 1.1 and adequate organ function. Results: Twenty-two patients were enrolled in 6 dose levels, 2 with daily dosing and 4 with twicedaily dosing ranging from 1 to 5 grams daily. All were evaluated for toxicity and 20 for response. No treatment-related dose-limiting toxicities (DLTs) were reported and the recommended phase II dose (RP2D) was determined to be 2.5 g twice daily. Seven adverse events in 5 patients were reported as possibly drug-related; 6 were GI toxicity and 1 was a skin disorder. All were grade 1 except one grade 2 vomiting. No RECIST responses were seen. Six pts were treated with > 2 cycles; one for 8 cycles. Four patients had reductions in TGF –β and EGF, exploratory biomarkers possibly suggestive of a drug effect. Plasma half-lives of 1 -2 hours were noted for all parent drug chemical markers with no accumulation over time. Conclusion: OMN54 was well tolerated, with no DLTs observed. Further studies at the RP2D will assess the biological activity." @default.
- W3048309245 created "2020-08-13" @default.
- W3048309245 creator A5001731680 @default.
- W3048309245 creator A5005876352 @default.
- W3048309245 creator A5014691774 @default.
- W3048309245 creator A5018814326 @default.
- W3048309245 creator A5036875007 @default.
- W3048309245 creator A5055681005 @default.
- W3048309245 creator A5067468792 @default.
- W3048309245 creator A5074506924 @default.
- W3048309245 creator A5078857320 @default.
- W3048309245 creator A5079164469 @default.
- W3048309245 creator A5087150696 @default.
- W3048309245 date "2020-11-06" @default.
- W3048309245 modified "2023-09-23" @default.
- W3048309245 title "A Phase I Study of OMN54 (Aneustat™) in Patients with Advanced Malignancies" @default.
- W3048309245 cites W1794942343 @default.
- W3048309245 cites W1975582371 @default.
- W3048309245 cites W1995515206 @default.
- W3048309245 cites W2015578154 @default.
- W3048309245 cites W2019607817 @default.
- W3048309245 cites W2025415662 @default.
- W3048309245 cites W2114830715 @default.
- W3048309245 cites W2117864836 @default.
- W3048309245 cites W2139911664 @default.
- W3048309245 cites W2146895137 @default.
- W3048309245 cites W2154066769 @default.
- W3048309245 cites W2787764040 @default.
- W3048309245 cites W2794273511 @default.
- W3048309245 cites W4229580929 @default.
- W3048309245 doi "https://doi.org/10.2174/1574893615999200601130946" @default.
- W3048309245 hasPublicationYear "2020" @default.
- W3048309245 type Work @default.
- W3048309245 sameAs 3048309245 @default.
- W3048309245 citedByCount "0" @default.
- W3048309245 crossrefType "journal-article" @default.
- W3048309245 hasAuthorship W3048309245A5001731680 @default.
- W3048309245 hasAuthorship W3048309245A5005876352 @default.
- W3048309245 hasAuthorship W3048309245A5014691774 @default.
- W3048309245 hasAuthorship W3048309245A5018814326 @default.
- W3048309245 hasAuthorship W3048309245A5036875007 @default.
- W3048309245 hasAuthorship W3048309245A5055681005 @default.
- W3048309245 hasAuthorship W3048309245A5067468792 @default.
- W3048309245 hasAuthorship W3048309245A5074506924 @default.
- W3048309245 hasAuthorship W3048309245A5078857320 @default.
- W3048309245 hasAuthorship W3048309245A5079164469 @default.
- W3048309245 hasAuthorship W3048309245A5087150696 @default.
- W3048309245 hasConcept C112705442 @default.
- W3048309245 hasConcept C126322002 @default.
- W3048309245 hasConcept C197934379 @default.
- W3048309245 hasConcept C22979827 @default.
- W3048309245 hasConcept C2777288759 @default.
- W3048309245 hasConcept C29730261 @default.
- W3048309245 hasConcept C71924100 @default.
- W3048309245 hasConcept C90924648 @default.
- W3048309245 hasConcept C98274493 @default.
- W3048309245 hasConceptScore W3048309245C112705442 @default.
- W3048309245 hasConceptScore W3048309245C126322002 @default.
- W3048309245 hasConceptScore W3048309245C197934379 @default.
- W3048309245 hasConceptScore W3048309245C22979827 @default.
- W3048309245 hasConceptScore W3048309245C2777288759 @default.
- W3048309245 hasConceptScore W3048309245C29730261 @default.
- W3048309245 hasConceptScore W3048309245C71924100 @default.
- W3048309245 hasConceptScore W3048309245C90924648 @default.
- W3048309245 hasConceptScore W3048309245C98274493 @default.
- W3048309245 hasLocation W30483092451 @default.
- W3048309245 hasOpenAccess W3048309245 @default.
- W3048309245 hasPrimaryLocation W30483092451 @default.
- W3048309245 hasRelatedWork W11056235 @default.
- W3048309245 hasRelatedWork W11432775 @default.
- W3048309245 hasRelatedWork W14082197 @default.
- W3048309245 hasRelatedWork W16130937 @default.
- W3048309245 hasRelatedWork W17661410 @default.
- W3048309245 hasRelatedWork W21039186 @default.
- W3048309245 hasRelatedWork W21586948 @default.
- W3048309245 hasRelatedWork W392153 @default.
- W3048309245 hasRelatedWork W7586573 @default.
- W3048309245 hasRelatedWork W4007547 @default.
- W3048309245 isParatext "false" @default.
- W3048309245 isRetracted "false" @default.
- W3048309245 magId "3048309245" @default.
- W3048309245 workType "article" @default.